
==== Front
Sci Rep
Sci Rep
Scientific Reports
2045-2322
Nature Publishing Group UK London

39251790
71558
10.1038/s41598-024-71558-1
Article
Immunogenetic profiles of 9 human herpes virus envelope glycoproteins
Georgopoulos Apostolos P. omega@umn.edu

123
James Lisa M. 124
1 https://ror.org/02ry60714 grid.410394.b 0000 0004 0419 8667 The HLA Research Group, Brain Sciences Center, Department of Veterans Affairs Health Care System, Minneapolis VAMC, One Veterans Drive, Minneapolis, MN 55417 USA
2 grid.17635.36 0000000419368657 Department of Neuroscience, University of Minnesota Medical School, Minneapolis, MN USA
3 grid.17635.36 0000000419368657 Institute for Health Informatics, University of Minnesota Medical School, Minneapolis, MN USA
4 grid.17635.36 0000000419368657 Department of Psychiatry, University of Minnesota Medical School, Minneapolis, MN USA
9 9 2024
9 9 2024
2024
14 2092420 4 2024
29 8 2024
© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Human herpes viruses (HHV) are ubiquitous and have been implicated in numerous long-term health conditions. Since the association between viral exposure and long-term health impacts is partially influenced by variation in human leukocyte antigen (HLA) genes, we evaluated in silico the binding affinities of 9 HHV envelope glycoproteins with 127 common HLA Class I and Class II molecules. The findings show substantial variability in HHV binding affinity across viruses, HLA Class, HLA genes, and HLA alleles. Specific findings were as follows: (1) the predicted binding affinities of HHVs were characterized by four distinct groupings—[HHV1, HHV2], [HHV3, HHV4, HHV5], [HHV6A], [HHV6B, HHV7, HHV8]—with relatively lower binding affinities for HHV1, HHV2, and HHV6a compared to other HHVs; (2) significantly higher binding affinity was found for HLA Class I relative to Class II; (3) analyses within each class demonstrated that alleles of the C gene (for Class I) and DRB1 gene (for Class II) had the highest binding affinities; and (4) for each virus, predicted binding affinity to specific alleles varied, with HHV6a having the lowest affinity for HHV-HLA complexes, and HHV3, HHV4, and HHV5 having the highest. Since HLA-antigen binding is the first step in initiating an immune response to foreign antigens, these relative differences in HHV binding affinities are likely to influence long-term health impacts such that the cells infected with viruses associated with higher binding affinities across common HLA alleles may be more reduced in numbers, thereby lowering the potential for long-term sequelae of their infections.

Keywords

Human herpes viruses
Binding affinity
Human leukocyte antigen (HLA)
Subject terms

Computational biology and bioinformatics
Genetics
Immunology
Microbiology
Diseases
Medical research
http://dx.doi.org/10.13039/100016868 University of Minnesota Foundation http://dx.doi.org/10.13039/100000738 U.S. Department of Veterans Affairs issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Human herpes viruses (HHV) are practically ubiquitous viruses that can establish lifelong infection characterized by alternating periods of latency and reactivation1–3. HHVs include herpes simplex virus 1 (HSV1/HHV1) and HSV2/HV2, varicella zoster virus (VZV/HHV3), Epstein-Barr virus (EBV/ HHV4), cytomegalovirus (CMV/HHV5), HHV6A, HHV6B, HHV7, and Kaposi’s sarcoma virus (HHV8). As a family of viruses, herpesviridae tropism spans multiple systems4, and HHVs have been implicated in numerous long-term health conditions including autoimmune disorders, neoplasms, and neurodegenerative conditions5,6.

The association between viral exposure and long-term health impacts is partially influenced by individual variation in human leukocyte antigen (HLA) genes7–10. Located on chromosome 6, the HLA region is the most highly polymorphic of the human genome11. Small differences, even single amino acid changes in the binding groove, can alter HLA-antigen binding12, thereby influencing foreign antigen elimination and disease susceptibility8,11. HLA genes code for cell-surface glycoproteins that present bound viral epitopes to T cells, signaling immune system responses aimed at virus elimination. Each individual possesses 12 HLA alleles, inherited in a Mendelian fashion, including two of each of the HLA Class I genes (HLA-A, HLA-B, and HLA-C) and two of each of the HLA Class II genes (HLA-DR, HLA-DQ, HLA-DP). Glycoproteins of the two classes operate in concert albeit via different mechanisms and timeframes. HLA Class I, which are expressed on all nucleated cells, signal destruction of an infected cell by binding and transporting cytosolic virus epitopes to the cell surface for presentation to cytotoxic CD8 + T cells. HLA Class II molecules, which are expressed on lymphocytes and professional antigen presenting cells, bind and present endocytosed exogenous antigen epitopes to CD4 + T cells to stimulate antibody production and long-term adaptive immunity. Developing long-term immunity in the event of virus re-exposure occurs over weeks to months compared to the rapid elimination of infected cells via the HLA Class I system13.

It is reasonable to hypothesize that rapid elimination of viral antigens by HLA Class I molecules may reduce viral latency and, consequently, reduce long-term sequelae of viral infections. In light of the high degree of HLA polymorphism, however, the immune response to a HLA-virus antigen complex varies, meaning that some HLA-antigen complexes will be more efficient in mounting an immune response to a given virus than others. Indeed, this is exemplified by slowed progression and control of human immunodeficiency virus (HIV) in carriers of certain HLA alleles (for example, HLA-B*27:05 and B*57:01), as compared to rapid disease progression associated with other HLA alleles (e.g., B*35:01)14. A recent review synthesizing genetic associations of HLA with herpesvirus infection and disease found that most HLA genetic associations are virus- or disease- specific, although certain allotypes were broadly associated with susceptibility or control across herpes viruses15. We hypothesize that observed differences in HLA associations with HHVs are related to immune response of HHV-HLA pairs, the first step of which hinges on sufficient HLA-virus antigen binding affinity. Thus, in this study we used an in silico approach to evaluate the binding affinity of 9 HHV proteins with 127 common HLA Class I (n = 69) and Class II (n = 58) antigens.

Results

Predicted binding affinities (PBA) of HHV proteins with HLA class I and II molecules

The HHV PBAs of the 9 HHV (Table 1) and 127 HLA Class I and II alleles (Tables 2 and 3) are given in Table S1 in Supplementary Material. The effects of HLA Class on these PBAs were evaluated using a repeated measures analysis of variance (ANOVA), where HHV PBA was the “Within-Subjects” factor and HLA Class was the “Between-Subjects” fixed factor. The results revealed a highly significant effect of HHV on PBA (Fig. 1A; P < 0.001, Greenhouse–Geisser test) and four distinct PBA groupings (color-coded in Fig. 1A): [HHV1, HHV2], [HHV3, HHV4, HHV5], [HHV6A], [HHV6B, HHV7, HHV8]. The same groupings were found using multidimensional scaling (MDS), occupying 4 distinct quadrants in the MDS map (Fig. 1B). Table 1 Viral proteins used.

Index	Virus	Protein description	UniprotKB ID	AA	
1	HHV1	Envelope glycoprotein D	Q69091	394	
2	HHV2	Envelope glycoprotein D	P03172	393	
3	HHV3	Envelope glycoprotein E	Q9J3M8	623	
4	HHV4	Envelope glycoprotein B	P03188	897	
5	HHV5	Envelope glycoprotein B	P06473	906	
6	HHV6A	Envelope glycoprotein Q2	P0DOE0	214	
7	HHV6B	Envelope glycoprotein Q1	Q9QJ11	516	
8	HHV7	Envelope glycoprotein H	P52353	690	
9	HHV8	Envelope glycoprotein H	F5HAK9	730	

Table 2 The 69 HLA Class I alleles used.

Index	Gene A	Index	Gene B	Index	Gene C	
1	A*01:01	21	B*07:02	57	C*01:02	
2	A*02:01	22	B*08:01	58	C*03:03	
3	A*02:05	23	B*13:02	59	C*04:01	
4	A*03:01	24	B*14:01	60	C*05:01	
5	A*11:01	25	B*14:02	61	C*06:02	
6	A*23:01	26	B*15:01	62	C*07:01	
7	A*24:02	27	B*15:17	63	C*07:02	
8	A*25:01	28	B*15:18	64	C*07:04	
9	A*26:01	29	B*18:01	65	C*12:02	
10	A*29:01	30	B*27:02	66	C*12:03	
11	A*29:02	31	B*27:05	67	C*14:02	
12	A*30:01	32	B*35:01	68	C*15:02	
13	A*30:02	33	B*35:02	69	C*16:01	
14	A*31:01	34	B*35:03		
15	A*32:01	35	B*35:08	
16	A*33:01	36	B*37:01	
17	A*33:03	37	B*38:01	
18	A*36:01	38	B*39:01	
19	A*68:01	39	B*39:06	
20	A*68:02	40	B*40:01	
	41	B*40:02	
42	B*41:01	
43	B*41:02	
44	B*44:02	
45	B*44:03	
46	B*44:05	
47	B*45:01	
48	B*47:01	
49	B*49:01	
50	B*50:01	
51	B*51:01	
52	B*52:01	
53	B*55:01	
54	B*56:01	
55	B*57:01	
56	B*58:01	

Table 3 The 58 HLA Class II alleles used.

Index	Gene	Index	Gene	Index	Gene	
1	DPB1*01:01	16	DQB1*02:01	30	DRB1*01:01	
2	DPB1*02:01	17	DQB1*02:02	31	DRB1*01:02	
3	DPB1*02:02	18	DQB1*03:01	32	DRB1*01:03	
4	DPB1*03:01	19	DQB1*03:02	33	DRB1*03:01	
5	DPB1*04:01	20	DQB1*03:03	34	DRB1*04:01	
6	DPB1*04:02	21	DQB1*04:02	35	DRB1*04:02	
7	DPB1*05:01	22	DQB1*05:01	36	DRB1*04:03	
8	DPB1*06:01	23	DQB1*05:02	37	DRB1*04:04	
9	DPB1*09:01	24	DQB1*05:03	38	DRB1*04:05	
10	DPB1*10:01	25	DQB1*06:01	39	DRB1*04:07	
11	DPB1*11:01	26	DQB1*06:02	40	DRB1*04:08	
12	DPB1*13:01	27	DQB1*06:03	41	DRB1*07:01	
13	DPB1*14:01	28	DQB1*06:04	42	DRB1*08:01	
14	DPB1*17:01	29	DQB1*06:09	43	DRB1*08:03	
15	DPB1*19:01			44	DRB1*09:01	
	45	DRB1*10:01	
46	DRB1*11:01	
47	DRB1*11:02	
48	DRB1*11:03	
49	DRB1*11:04	
50	DRB1*12:01	
51	DRB1*13:01	
52	DRB1*13:02	
53	DRB1*13:03	
54	DRB1*13:05	
55	DRB1*14:01	
56	DRB1*15:01	
57	DRB1*15:02	
58	DRB1*16:01	

Fig. 1 (A) Mean predicted binding affinity (± SEM) of the 9 HHV proteins analyzed across the 127 HLA alleles. (B) Plot of the derived HHV protein configuration yielded by the multidimensional scaling analysis. Viral proteins are color-coded to highlight the 4 distinct PBA groups.

With respect to HLA Class, Class I PBA was significantly higher than Class II (Fig. 2A, P < 0.001, F-test). Finally, with respect to HLA genes, we used a repeated measures ANOVA to evaluate the effect of Gene (“Between-Subjects fixed factor) within each Class. We found a statistically significant effect of Gene for both Class I (P = 0.01, F-test) and Class II (P = 0.038, F-test), with genes C and DRB1 having the highest PBAs (Fig. 2B,C, respectively).Fig. 2 A Mean predicted binding affinity (± SEM) of the 9 HHV proteins in the 2 HLA Classes (A), Class I genes (B), and Class II genes (C).

Variation of PBA across HLA alleles

The analyses above evaluated the overall effects of Virus, Class and Gene on PBA. Here we show the individual PBA values for all 127 HLA alleles and the 9 HHV viruses in Figs. 3 and 4. The PBA value of zero corresponds to lowest percentile rank of 1 (PBA = ln(1) = 0; see Methods), a conservative threshold for high binding affinity. It can be seen that (a) most PBAs are of high affinity (> 0), (b) the number of low affinity PBA differ across viruses, being highest for HHV6A and lowest for HHV3, HHV4 and HHV5, and (c) in all viruses but HHV6A, low affinity PBAs are confined to Class II. This variation in PBA across alleles and viruses is captured in the heatmap of Fig. 5.Fig. 3 Individual PBA values are plotted for viruses HHV1–HHV6A, as indicated. Red, high affinity PBA; blue, low affinity PBA. N = 127 for each plot.

Fig. 4 Individual PBA values are plotted for viruses HHV6B, HHV7 and HHV8, as indicated. Red, high affinity PBA; blue, low affinity PBA. N = 127 for each plot.

Fig. 5 Heatmap of PBAs across the 127 HLA alleles (rows) and the 9 viral proteins (columns). Red, high PBA values (Z-score ≥ 2); blue, low PBA values (Z-score ≤ -2).

Association of PBA with protein length

Since we tested all possible 9-AA (for Class I) and 15-AA (for Class II) epitopes, it is possible that PBA estimates could depend on protein length since longer proteins would afford more AA sequences to which HLA molecules could potentially bind. We evaluated this hypothesis by computing, for each allele, the Pearson correlation between PBA values and the number of amino acids in a protein (Table 1). We found the following (Table 4). (a) 18/127 (14.1%) of the correlations were negative (10 Class I, 8 Class II), speaking against the hypothesis above; an example is shown in Fig. 6A. (b) 95/127 (74.8%) correlations were not statistically significant, at a nominal threshold of P < 0.05, uncorrected for multiple comparisons; no correlation was significant at a threshold of P < 0.05/127, i.e. P < 0.000394, after the conservative Bonferroni correction or P < 0.000404, after the less conservative Šidák correction (see Methods); and (c) the percent of PBA variance explained by protein AA length (i.e. 100 x r2), irrespective of statistical significance, ranged from 0.001 to 78.5%, but was heavily skewed towards small values (median = 16.7%, mean ± SEM 24.9 ± 2.1%). An example of high positive correlation is shown in Fig. 6B. Overall, these results indicate that there is only a small overall contribution of protein length to PBA values. Table 4 Correlation between HHV PBA and the number of amino acids in the HHV protein (N = 9). *, P < 0.05.

Index	HLA allele	Class	Gene	r
Pearson	P-value	Percent of variance explained	
1	A*01:01	1	1	0.1414	0.7167	1.999	
2	A*02:01	1	1	0.7334	0.0245*	53.793	
3	A*02:05	1	1	0.8864	0.0015*	78.568	
4	A*03:01	1	1	0.3691	0.3284	13.620	
5	A*11:01	1	1	0.7155	0.0302*	51.197	
6	A*23:01	1	1	0.5215	0.1499	27.193	
7	A*24:02	1	1	0.4754	0.1958	22.605	
8	A*25:01	1	1	0.6672	0.0496*	44.516	
9	A*26:01	1	1	0.8258	0.0061*	68.197	
10	A*29:01	1	1	0.5064	0.1642	25.647	
11	A*29:02	1	1	0.5064	0.1642	25.647	
12	A*30:01	1	1	0.5019	0.1686	25.190	
13	A*30:02	1	1	0.1697	0.6625	2.879	
14	A*31:01	1	1	− 0.0005	0.9989	0.000	
15	A*32:01	1	1	0.7196	0.0288*	51.786	
16	A*33:01	1	1	− 0.0346	0.9296	0.120	
17	A*33:03	1	1	− 0.1377	0.7239	1.896	
18	A*36:01	1	1	− 0.5571	0.1192	31.038	
19	A*68:01	1	1	0.6239	0.0726	38.920	
20	A*68:02	1	1	0.8610	0.0029*	74.129	
21	B*07:02	1	2	0.3514	0.3538	12.347	
22	B*08:01	1	2	0.4557	0.2177	20.766	
23	B*13:02	1	2	0.7441	0.0215*	55.363	
24	B*14:01	1	2	0.2255	0.5596	5.085	
25	B*14:02	1	2	0.2255	0.5596	5.085	
26	B*15:01	1	2	0.6041	0.0849	36.497	
27	B*15:17	1	2	0.3886	0.3013	15.102	
28	B*15:18	1	2	0.5747	0.1055	33.030	
29	B*18:01	1	2	0.8092	0.0082*	65.481	
30	B*27:02	1	2	0.1412	0.7171	1.993	
31	B*27:05	1	2	0.1222	0.7541	1.494	
32	B*35:01	1	2	0.6533	0.0564	42.684	
33	B*35:02	1	2	− 0.1272	0.7443	1.619	
34	B*35:03	1	2	− 0.2384	0.5368	5.682	
35	B*35:08	1	2	0.6203	0.0747	38.483	
36	B*37:01	1	2	0.6997	0.0359*	48.952	
37	B*38:01	1	2	0.3403	0.3701	11.584	
38	B*39:01	1	2	− 0.1490	0.7019	2.221	
39	B*39:06	1	2	− 0.7481	0.0204*	55.959	
40	B*40:01	1	2	0.5616	0.1156	31.535	
41	B*40:02	1	2	0.7892	0.0114*	62.286	
42	B*41:01	1	2	0.7848	0.0123*	61.584	
43	B*41:02	1	2	0.4623	0.2102	21.375	
44	B*44:02	1	2	0.1335	0.7320	1.783	
45	B*44:03	1	2	0.2514	0.5140	6.322	
46	B*44:05	1	2	0.1068	0.7846	1.140	
47	B*45:01	1	2	0.8818	0.0017*	77.754	
48	B*47:01	1	2	0.2151	0.5784	4.627	
49	B*49:01	1	2	0.7972	0.0101*	63.560	
50	B*50:01	1	2	0.7929	0.0108*	62.868	
51	B*51:01	1	2	− 0.2813	0.4634	7.913	
52	B*52:01	1	2	0.2988	0.4348	8.926	
53	B*55:01	1	2	0.4628	0.2096	21.422	
54	B*56:01	1	2	0.1705	0.6610	2.907	
55	B*57:01	1	2	− 0.0663	0.8654	0.440	
56	B*58:01	1	2	0.1480	0.7040	2.190	
57	C*01:02	1	3	0.0073	0.9850	0.005	
58	C*03:03	1	3	0.3188	0.4030	10.164	
59	C*04:01	1	3	0.6436	0.0614	41.419	
60	C*05:01	1	3	0.7428	0.0219*	55.175	
61	C*06:02	1	3	0.1482	0.7036	2.196	
62	C*07:01	1	3	0.8779	0.0019*	77.075	
63	C*07:02	1	3	0.6494	0.0584	42.169	
64	C*07:04	1	3	0.7295	0.0257*	53.212	
65	C*12:02	1	3	0.3373	0.3747	11.377	
66	C*12:03	1	3	0.0723	0.8533	0.523	
67	C*14:02	1	3	0.2842	0.4585	8.079	
68	C*15:02	1	3	0.5929	0.0924	35.158	
69	C*16:01	1	3	0.2565	0.5052	6.581	
70	DPB1*01:01	2	4	0.4997	0.1708	24.969	
71	DPB1*02:01	2	4	0.4088	0.2746	16.714	
72	DPB1*02:02	2	4	0.4069	0.2771	16.554	
73	DPB1*03:01	2	4	0.7532	0.0191*	56.736	
74	DPB1*04:01	2	4	0.5051	0.1655	25.509	
75	DPB1*04:02	2	4	0.4019	0.2836	16.153	
76	DPB1*05:01	2	4	0.8815	0.0017*	77.703	
77	DPB1*06:01	2	4	0.7597	0.0175*	57.714	
78	DPB1*09:01	2	4	0.7099	0.0322*	50.392	
79	DPB1*10:01	2	4	0.7479	0.0205*	55.933	
80	DPB1*11:01	2	4	0.2491	0.5181	6.205	
81	DPB1*13:01	2	4	0.4097	0.2735	16.784	
82	DPB1*14:01	2	4	0.7369	0.0235	54.305	
83	DPB1*17:01	2	4	0.6677	0.0494*	44.579	
84	DPB1*19:01	2	4	0.4835	0.1873	23.380	
85	DQB1*02:01	2	5	0.2349	0.5430	5.517	
86	DQB1*02:02	2	5	0.2349	0.5430	5.517	
87	DQB1*03:01	2	5	0.1720	0.6581	2.959	
88	DQB1*03:02	2	5	0.3846	0.3068	14.790	
89	DQB1*03:03	2	5	0.0720	0.8539	0.519	
90	DQB1*04:02	2	5	0.0819	0.8341	0.670	
91	DQB1*05:01	2	5	0.4846	0.1862	23.483	
92	DQB1*05:02	2	5	0.3653	0.3337	13.343	
93	DQB1*05:03	2	5	0.2830	0.4607	8.006	
94	DQB1*06:01	2	5	0.7545	0.0188*	56.927	
95	DQB1*06:02	2	5	0.7915	0.0110*	62.651	
96	DQB1*06:03	2	5	− 0.0974	0.8031	0.950	
97	DQB1*06:04	2	5	0.5744	0.1057	32.993	
98	DQB1*06:09	2	5	0.6394	0.0637	40.879	
99	DRB1*01:01	2	6	0.1778	0.6471	3.163	
100	DRB1*01:02	2	6	0.2987	0.4349	8.923	
101	DRB1*01:03	2	6	0.1621	0.6770	2.626	
102	DRB1*03:01	2	6	− 0.1666	0.6684	2.775	
103	DRB1*04:01	2	6	− 0.1313	0.7363	1.724	
104	DRB1*04:02	2	6	0.4284	0.2499	18.356	
105	DRB1*04:03	2	6	0.1163	0.7657	1.353	
106	DRB1*04:04	2	6	0.3001	0.4327	9.006	
107	DRB1*04:05	2	6	0.0633	0.8714	0.401	
108	DRB1*04:07	2	6	0.0113	0.9771	0.013	
109	DRB1*04:08	2	6	0.0170	0.9653	0.029	
110	DRB1*07:01	2	6	0.7908	0.0112*	62.534	
111	DRB1*08:01	2	6	− 0.4362	0.2405	19.025	
112	DRB1*08:03	2	6	− 0.4704	0.2013	22.130	
113	DRB1*09:01	2	6	0.5371	0.1359	28.848	
114	DRB1*10:01	2	6	0.1782	0.6465	3.175	
115	DRB1*11:01	2	6	− 0.6965	0.0371*	48.514	
116	DRB1*11:02	2	6	0.2902	0.4488	8.421	
117	DRB1*11:03	2	6	0.3671	0.3311	13.475	
118	DRB1*11:04	2	6	0.7600	0.0175*	57.761	
119	DRB1*12:01	2	6	0.0863	0.8253	0.744	
120	DRB1*13:01	2	6	0.2902	0.4488	8.421	
121	DRB1*13:02	2	6	0.2990	0.4345	8.939	
122	DRB1*13:03	2	6	− 0.0736	0.8508	0.541	
123	DRB1*13:05	2	6	− 0.6965	0.0371*	48.514	
124	DRB1*14:01	2	6	0.7490	0.0202*	56.100	
125	DRB1*15:01	2	6	0.2329	0.5465	5.424	
126	DRB1*15:02	2	6	0.0310	0.9369	0.096	
127	DRB1*16:01	2	6	0.5425	0.1313	29.432	

Fig. 6 (A) negative association between PBA and number of amino acid (AA) residues of the HHV proteins (Table 1) for allele B*39:06. (B) positive association, for allele A*02:05.

Discussion

Here we evaluated binding affinities of 127 common HLA Class I and Class II alleles with envelope glycoproteins of 9 HHVs and documented substantial variability in the predicted binding affinities of HHVs with regard to HLA Class, gene, and allele. Since HLA–HHV antigen binding is a critical initial step in mounting an adaptive immune response to a viral infection, these findings highlight relative differences in binding affinities of specific HHVs with common HLA Class I and Class II alleles and point to enhanced ability of certain HLA alleles to facilitate a more effective adaptive immune system response to HHVs that bind with higher affinity to common HLA alleles. In the absence of high affinity HLA-HHV complex binding, the virus may persist16, establish latency17, and contribute to subsequent long-term health impacts18,19.

The HLA-HHV binding affinities here fell into four distinct groups, two of which were characterized by distinctly lower binding affinities. Specifically, HHV1/HHV2 and HHV6a, neurotropic viruses that have been implicated (to varying degrees) with neurological conditions20–23, had low binding affinities overall (Fig. 1) and particularly for HLA Class II (Figs. 3, 4, 5). HHV1 and HHV2, commonly referred to as herpes simplex virus -1 (HSV-1) and -2 (HSV-2), cause lifelong infections characterized by periods of latency and reactivation in the form of orolabial (HSV-1) or genital (HSV-2) lesions. The seroprevalence of HSV-1, which is typically acquired by oral contact, in individuals between the ages of 14 and 49 is estimated at 54% whereas the seroprevalence of HSV-2, which is typically sexually transmitted, is 16% in the same age range24. Extensive research supports a prominent role of HSV-1 in dementia20; HSV-2 has been shown to increase HIV acquisition25 and is associated with neurological complications26. Part of the roseola family, HHV6A infection is very common early in life, and, as a neurotropic virus, is commonly detected in the brains of healthy individuals as well as those with neurological diseases27–29. Notably, HHV6A has been shown to integrate into the host germline, allowing for generational transmission of the HHV6A viral genome30. The relatively low binding affinity of HHV1, HHV2, and HHV6A with common HLA alleles may hinder efficient elimination of those viruses, potentially contributing to the development of subsequent neurological effects. Despite their relatively higher overall binding affinities, several of the HHVs comprising the other two groupings (HHV3, HHV4, HHV5; HHV6b, HHV7, HHV8) have also been implicated in long-term health conditions including various cancers, neurological, and autoimmune disorders19,31–35. It is worth noting that even for the 6 viruses associated with higher overall predicted binding affinities to common HLA alleles, there was still substantial variability in predicted binding affinity across alleles (Figs. 3, 4, 5), indicating that some are preferentially able to bind with high affinity compared to others. Thus, the findings suggest that some HHVs are overall more readily handled by HLA-mediated adaptive immune system mechanisms than others, due to their superior binding affinity with common HLA alleles. Nonetheless, for all of the HHVs, the effectiveness of the adaptive immune system response is predicated on high-affinity HLA-HHV binding. To that end, we hypothesize that HHV latency and reactivation as well as long-term disease associations are HLA-dependent.

It is noteworthy that the predicted binding affinities of HHVs with Class I HLA molecules were significantly higher than those of Class II. HLA Class I and Class II play different albeit complementary roles in the adaptive immune response to viruses. HLA Class I promotes rapid elimination of infected cells via cytotoxic CD8 + T cells, whereas Class II contributes to long-term protection via antibody production and immunological memory, a process that can take months13. We propose that rapid elimination of HHVs by binding with HLA Class I to form high affinity HHV-HLA complexes may reduce the potential of the virus to establish latency, thereby reducing the likelihood of viral reactivation and associated diseases, as has been established in the case of early efficient elimination of HIV by certain Class I alleles36. This rapid elimination via Class I mediated cytotoxic T cells does not preclude development of Class II mediated antibody production; indeed, much of the population is seropositive for one or more HHVs (1,2,3). In some cases, seropositivity is associated with disease19,37, suggesting that antibodies reflective of seropositivity do not necessarily confer protection. For both HLA Class I and II, however, adaptive immune protection against HHVs are HLA-dependent in that absence of sufficient HHV-HLA binding affinity inhibits presentation to CD8 + or CD4 + T cells necessary for signaling destruction of infected cells (Class I) or antibody production (Class II), permitting the viral antigen to persist.

Class I HLA-C and Class II HLA-DRB1 genes were associated with higher binding affinity to HHVs than other genes within each respective HLA class. Compared to other classical HLA Class I genes (A and B), HLA-C is unique in that it is less frequently expressed on the cell surface but is the only HLA Class I gene for which virtually all allotypes serve as a natural ligand for multiple types of killer-cell immunoglobulin-like receptors (KIR) which are expressed on natural killer cells that are known to control infected cells efficiently38. As reviewed elsewhere38, mounting research has documented that HLA-C, in combination with KIR, influences control and/or progression of various viral infections including HIV, hepatitis C, and CMV, a member of the herpesviridae family (HHV5). Alleles of the DRB1 gene have been associated with both protection and susceptibility to various conditions including numerous autoimmune disorders7,39,40, many of which are associated with virus exposure41. The current study shines the spotlight more prominently on Class I HLA-C and Class II HLA-DRB1 in influencing the outcome and progression of various HHVs and points to superior binding affinity of HLA-C and HLA-DRB1 as an important underlying mechanism.

The present findings, which document that binding affinity of a given HHV varies across HLA Class I and Class II alleles, must be considered with several qualifications. First, to ensure their survival, HHVs are notorious for utilizing immune evasion mechanisms, several of which involve downregulation of HLA or interference with transport or loading of antigenic peptides which may impair viral elimination even in the case of a strong antiviral immune response42. Second, the focus here is on virus antigen–HLA binding since that is a necessary first step in adaptive immunity; the extent of the human immune response is also partially dependent on immunogenicity of the antigen-HLA complex. Thus, it is possible that some of the high affinity virus-HLA associations documented here may not produce a sufficient immunogenic response against viral antigens. Third, the analyses focused on 127 common HLA Class I and Class II alleles; it is possible that other less common alleles that were not investigated here are capable of forming highly immunogenic complexes. Nonetheless, focusing on globally common alleles permits greater generalization of the findings. Finally, for each virus, we analyzed binding affinity of a single protein of a single strain—specifically, an envelope glycoprotein that is involved in viral entry into the cell. It is unclear to what extent the present findings extend to other proteins and other strains of each of the viruses investigated; although such analyses are beyond the scope of the present paper, they are currently underway.

Materials and methods

HHV proteins

We estimated the binding affinity (for each one of the 69 Class I alleles and 58 Class II alleles) of envelope glycoproteins of 9 HHV viruses (HHV1, HHV2, HHV3, HHV4, HHV5, HHV6A, HHV6B, HHV7, HHV8). Details of the proteins analyzed are given in Table 1 and their amino acid (AA) sequences are given in Table 2S in Supplementary Material. These proteins are involved in virus entry into the cell43 have been widely used in HHV-immunology research, including vaccine development44–53.

HLA alleles

We used 69 common HLA Class I alleles (Table 2) and 58 common HLA Class II alleles (Table 3) that we have employed in previous studies54. Briefly, we obtained the population frequency in 2019 of 127 common HLA Class I and Class II alleles from 14 Continental Western European Countries (Austria, Belgium, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Portugal, Norway, Spain, Sweden, and Switzerland). There was a total of 2746 entries of alleles from these countries, comprising 844 distinct alleles. Of those, 69 Class I alleles and 58 Class II alleles occurred in 9 or more countries, with a minimum frequency (in any country) of 0.01. Although those alleles were selected based on their frequency in Europe, they have been found to the common overall across 6 world populations55, namely African/African American (AFA), Asian/Pacific Islands (API), European/European descent (EURO), Middle East/North Coast of Africa (MENA), South or Central America/Hispanic/Latino (HIS), Native American (NAM), Unknown/not asked/multiple ancestries/other (UKN), and total (TOTAL). All but allele A*36:01 were Common in each one of the 6 populations above; allele A*36:01 was Intermediate in API and EURO populations, and Common in the remainder populations, and was Common across the 6 populations.

In silico determination of predicted binding affinity of HLA Class I and Class II molecules

Predicted binding affinities were obtained for viral protein epitopes using the Immune Epitope Database (IEDB) NetMHCpan (ver. 4.1) tool56,57. More specifically, we used the sliding window approach58–60 to test exhaustively all possible linear 9-mer (for HLA-I predictions) and 15-mer (for HLA-II predictions) AA residue epitopes of the 9 viral proteins analyzed (Table 1). The method is illustrated in Figs. 7 and 8 for the HHV4 virus protein. For each epitope-HLA molecule tested, this tool gives, as an output, the percentile rank of binding affinity of the HLA molecule and the epitope among predicted binding affinities of the same HLA molecule to a large number of different peptides of the same AA length; the smaller the percentile rank, the better the binding affinity. Now, given a protein of N amino acid length and an epitope length of k AA, there are N-k binding affinity predictions, i.e. N-k percentile ranks. Of these predictions, for each viral protein and HLA molecule tested, we retained the lowest percentile rank (LPR) as the best possible binding affinity of the protein-HLA molecule pair. We then applied two transformations on LPR. First, we took its inverse, so that higher values mean better binding affinities for more intuitive interpretation:Fig. 7 Sliding window method for HLA Class I analyses (window length = 9 AA), illustrated for HHV4.

Fig. 8 Sliding window method for HLA Class II analyses (window length = 15 AA), illustrated for HHV4.

1 LPR′=1LPR

The LPR′ distribution was heavily skewed to the left (Fig. 9A), resembling an exponential distribution. Therefore, LPR′ values were (natural) log transformed to normalize its distribution for quantitative analyses (Fig. 9B):Fig. 9 Frequency distributions of LPR′ (Eq. 1) (A, skewed to the left) and its log-transformed PBA values (Eq. 2) (B, unimodal).

2 Predicted Binding Affinity(PBA):PBA=ln(LPR′)

Give the logarithmic transformation above, PBA > 0 indicate LPR′>1, whereas PBA < 0 indicate LPR′<1.

Statistical analyses

The IBM-SPSS statistical package (version 29.0.1.1 244) was used for implementing statistical analyses. Standard statistical methods were used, including descriptive statistics, ANOVA, Pearson correlation, etc. All P-values reported are 2-sided, a=0.05.

Statistical significance uncorrected for multiple comparisons

For this condition, with a=0.05, P < 0.05 indicated a statistically significant effect for each one of 127 correlations computed between viral PBA and number of amino acids in a viral protein.

Statistical significance corrected for multiple comparisons

Here we computed P values adjusted for the 127 correlations above in two ways, as follows. The first adjustment was the Bonferroni correction, where3 P(Bonferroni adjusted)=0.05127=0.000394

The second was the Šidák correction, where4 P(Svida´k adjusted)=1-1-0.051127=1-0.999596=0.000404

Multidimensional scaling

The potential groupings of the 9 HHV PBAs were evaluated by MDS using the ALSCAL procedure with the following parameters: Model: Euclidean distance; Level of measurement: ratio; Conditionality: matrix; Dimensions: minimum 2, maximum 2; S-stress convergence: 0.0001, minimum s-stress value: 0.005, maximum number of iterations: 30).

Visualization

For PBA visualization, the Heatmapper tool61 was used (http://www.heatmapper.ca/; accessed on July 13, 2024).

Supplementary Information

Supplementary Information.

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-024-71558-1.

Author contributions

A.P.G. and L.M.J. retrieved the data. A.P.G. performed data analysis. A.P.G. made figures. L.M.J. and A.P.G. wrote, edited and approved the paper.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Partial funding for this study was provided by the University of Minnesota (the Anita Kunin Chair in Women’s Healthy Brain Aging, the Brain and Genomics Fund, the McKnight Presidential Chair of Cognitive Neuroscience, and the American Legion Brain Sciences Chair) and the U.S. Department of Veterans Affairs. The sponsors had no role in the current study design, analysis or interpretation, or in the writing of this paper. The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government.

Data availability

All data used were retrieved from freely accessible websites and, as such, are publicly and freely available at http://www.biostatistics.online/ineo-epp/neoantigen.php].

Competing interests

The authors declare no competing interests.

Ethical approval

This article does not contain any studies with human participants performed by any of the authors.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Staras A Seroprevalence of cytomegalovirus infection in the United States, 1988–1994 Clin. Infect. Dis. 2006 43 1143 1151 10.1086/508173 17029132
Staras, A. et al. Seroprevalence of cytomegalovirus infection in the United States, 1988–1994. Clin. Infect. Dis. 43, 1143–1151. 10.1086/508173 (2006).17029132 10.1086/508173
2. Wald A Corey L Arvin A Persistence in the population: epidemiology, transmission Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis, Chapter 36 2007 Cambridge University Press
Wald, A. & Corey, L. Persistence in the population: epidemiology, transmission. In Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis, Chapter 36 (eds Arvin, A. et al.) (Cambridge University Press, 2007).
3. McQuillan, G., Kruszon-Moran, D., Flagg, E. W. & Paulose-Ram, R. Prevalence of herpes simplex virus type 1 and type 2 in persons aged 14–49: United States, 2015–2016. NCHS Data Brief, no 304. Hyattsville, MD: National Center for Health Statistics; 2018.
4. Ye S An atlas of human viruses provides new insights into diversity and tissue tropism of human viruses Bioinformatics. 2022 38 3087 3093 10.1093/bioinformatics/btac275 35435220
Ye, S. et al. An atlas of human viruses provides new insights into diversity and tissue tropism of human viruses. Bioinformatics. 38, 3087–3093. 10.1093/bioinformatics/btac275 (2022).35435220 10.1093/bioinformatics/btac275
5. De Francesco MA Herpesviridae, neurodegenerative disorders and autoimmune diseases: What is the relationship between them? Viruses. 2024 16 133 10.3390/v16010133 38257833
De Francesco, M. A. Herpesviridae, neurodegenerative disorders and autoimmune diseases: What is the relationship between them?. Viruses. 16, 133. 10.3390/v16010133 (2024).38257833 10.3390/v16010133
6. Morales-Sánchez A Fuentes-Pananá EM Human viruses and cancer Viruses 2014 6 4047 4079 10.3390/v6104047 25341666
Morales-Sánchez, A. & Fuentes-Pananá, E. M. Human viruses and cancer. Viruses 6, 4047–4079. 10.3390/v6104047 (2014).25341666 10.3390/v6104047
7. Dendrou CA Petersen J Rossjohn J Fugger L HLA variation and disease Nat. Rev. Immunol. 2018 18 325 339 10.1038/nri.2017.143 29292391
Dendrou, C. A., Petersen, J., Rossjohn, J. & Fugger, L. HLA variation and disease. Nat. Rev. Immunol. 18, 325–339. 10.1038/nri.2017.143 (2018).29292391 10.1038/nri.2017.143
8. Blackwell JM Jamieson SE Burgner D HLA and infectious diseases Clin. Microbiol. Rev. 2009 10.1128/cmr.00048-08 19366919
Blackwell, J. M., Jamieson, S. E. & Burgner, D. HLA and infectious diseases. Clin. Microbiol. Rev.10.1128/cmr.00048-08 (2009).19366919 10.1128/cmr.00048-08
9. James LM Georgopoulos AP Breast cancer, viruses, and human leukocyte antigen (HLA) Sci. Rep. 2024 14 16179 10.1038/s41598-024-65707-9 39003313
James, L. M. & Georgopoulos, A. P. Breast cancer, viruses, and human leukocyte antigen (HLA). Sci. Rep. 14, 16179. 10.1038/s41598-024-65707-9 (2024).39003313 10.1038/s41598-024-65707-9
10. Madeleine MM Comprehensive analysis of HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 loci and squamous cell cervical cancer risk Cancer Res. 2008 68 3532 3539 10.1158/0008-5472.CAN-07-6471 18451182
Madeleine, M. M. et al. Comprehensive analysis of HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 loci and squamous cell cervical cancer risk. Cancer Res. 68, 3532–3539. 10.1158/0008-5472.CAN-07-6471 (2008).18451182 10.1158/0008-5472.CAN-07-6471
11. Trowsdale J Knight JC Major histocompatibility complex genomics and human disease Annu. Rev. Genomics Hum. Genet. 2013 14 301 323 10.1146/annurev-genom-091212-153455 23875801
Trowsdale, J. & Knight, J. C. Major histocompatibility complex genomics and human disease. Annu. Rev. Genomics Hum. Genet. 14, 301–323. 10.1146/annurev-genom-091212-153455 (2013).23875801 10.1146/annurev-genom-091212-153455
12. Hov JR Electrostatic modifications of the human leukocyte antigen-DR P9 peptide-binding pocket and susceptibility to primary sclerosing cholangitis Hepatology. 2011 53 1967 1976 10.1002/hep.24299 21413052
Hov, J. R. et al. Electrostatic modifications of the human leukocyte antigen-DR P9 peptide-binding pocket and susceptibility to primary sclerosing cholangitis. Hepatology. 53, 1967–1976. 10.1002/hep.24299 (2011).21413052 10.1002/hep.24299
13. Sego TJ A modular framework for multiscale, multicellular, spatiotemporal modeling of acute primary viral infection and immune response in epithelial tissues and its application to drug therapy timing and effectiveness PLoS Comput. Biol. 2020 16 e1008451 10.1371/journal.pcbi.1008451 33347439
Sego, T. J. et al. A modular framework for multiscale, multicellular, spatiotemporal modeling of acute primary viral infection and immune response in epithelial tissues and its application to drug therapy timing and effectiveness. PLoS Comput. Biol. 16, e1008451. 10.1371/journal.pcbi.1008451 (2020).33347439 10.1371/journal.pcbi.1008451
14. Crux NB Elahi S Human leukocyte antigen (HLA) and immune regulation: How do classical and non-classical HLA alleles modulate immune response to human immunodeficiency virus and hepatitis c virus infections? Front. Immunol. 2017 8 832 10.3389/fimmu.2017.00832 28769934
Crux, N. B. & Elahi, S. Human leukocyte antigen (HLA) and immune regulation: How do classical and non-classical HLA alleles modulate immune response to human immunodeficiency virus and hepatitis c virus infections?. Front. Immunol. 8, 832. 10.3389/fimmu.2017.00832 (2017).28769934 10.3389/fimmu.2017.00832
15. Palmer WH Norman PJ The impact of HLA polymorphism on herpesvirus infection and disease Immunogenetics. 2023 75 231 247 10.1007/s00251-022-01288-z 36595060
Palmer, W. H. & Norman, P. J. The impact of HLA polymorphism on herpesvirus infection and disease. Immunogenetics. 75, 231–247. 10.1007/s00251-022-01288-z (2023).36595060 10.1007/s00251-022-01288-z
16. James LM Georgopoulos AP Persistent antigens hypothesis: The human leukocyte antigen (HLA) connection J. Neurol. Neuromed. 2018 3 27 31 10.29245/2572.942X/2018/6.1235
James, L. M. & Georgopoulos, A. P. Persistent antigens hypothesis: The human leukocyte antigen (HLA) connection. J. Neurol. Neuromed. 3, 27–31. 10.29245/2572.942X/2018/6.1235 (2018).10.29245/2572.942X/2018/6.1235
17. Grinde B Herpesviruses: Latency and reactivation–viral strategies and host response J. Oral Microbiol. 2013 5 22766 10.3402/jom.v5i0.22766
Grinde, B. Herpesviruses: Latency and reactivation–viral strategies and host response. J. Oral Microbiol. 5, 22766. 10.3402/jom.v5i0.22766 (2013).10.3402/jom.v5i0.22766
18. Watson AMM Persistent infection with neurotropic herpes viruses and cognitive impairment Psychol. Med. 2013 43 1023 1031 10.1017/S003329171200195X 22975221
Watson, A. M. M. et al. Persistent infection with neurotropic herpes viruses and cognitive impairment. Psychol. Med. 43, 1023–1031. 10.1017/S003329171200195X (2013).22975221 10.1017/S003329171200195X
19. Chakravorty S Afzali B Kazemian M EBV-associated diseases: Current therapeutics and emerging technologies Front. Immunol. 2022 13 1059133 10.3389/fimmu.2022.1059133 36389670
Chakravorty, S., Afzali, B. & Kazemian, M. EBV-associated diseases: Current therapeutics and emerging technologies. Front. Immunol. 13, 1059133. 10.3389/fimmu.2022.1059133 (2022).36389670 10.3389/fimmu.2022.1059133
20. Itzhaki RF Overwhelming evidence for a major role for Herpes Simplex Virus Type 1 (HSV1) in Alzheimer's Disease (AD); Underwhelming evidence against Vaccines 2021 9 679 10.3390/vaccines9060679 34205498
Itzhaki, R. F. Overwhelming evidence for a major role for Herpes Simplex Virus Type 1 (HSV1) in Alzheimer’s Disease (AD); Underwhelming evidence against. Vaccines 9, 679. 10.3390/vaccines9060679 (2021).34205498 10.3390/vaccines9060679
21. Komaroff AL Pellett PE Jacobson S Human Herpesviruses 6A and 6B in brain diseases: Association versus causation Clin. Microbiol. Rev. 2020 34 e00143 e220 10.1128/CMR.00143-20 33177186
Komaroff, A. L., Pellett, P. E. & Jacobson, S. Human Herpesviruses 6A and 6B in brain diseases: Association versus causation. Clin. Microbiol. Rev. 34, e00143-e220. 10.1128/CMR.00143-20 (2020).33177186 10.1128/CMR.00143-20
22. Warren-Gash C Human herpesvirus infections and dementia or mild cognitive impairment: A systematic review and meta-analysis Sci. Rep. 2019 9 4743 10.1038/s41598-019-41218-w 30894595
Warren-Gash, C. et al. Human herpesvirus infections and dementia or mild cognitive impairment: A systematic review and meta-analysis. Sci. Rep. 9, 4743. 10.1038/s41598-019-41218-w (2019).30894595 10.1038/s41598-019-41218-w
23. Tzeng NS Anti-herpetic medications and reduced risk of dementia in patients with herpes simplex virus infections—A nationwide, population-based cohort study in Taiwan Neurotherapeutics. 2018 15 417 429 10.1007/s13311-018-0611-x 29488144
Tzeng, N. S. et al. Anti-herpetic medications and reduced risk of dementia in patients with herpes simplex virus infections—A nationwide, population-based cohort study in Taiwan. Neurotherapeutics. 15, 417–429. 10.1007/s13311-018-0611-x (2018).29488144 10.1007/s13311-018-0611-x
24. Bradley H Markowitz LE Gibson T McQuillan GM Seroprevalence of herpes simplex virus types 1 and 2—United States, 1999–2010 J. Infect. Dis. 2014 209 325 333 10.1093/infdis/jit458 24136792
Bradley, H., Markowitz, L. E., Gibson, T. & McQuillan, G. M. Seroprevalence of herpes simplex virus types 1 and 2—United States, 1999–2010. J. Infect. Dis. 209, 325–333. 10.1093/infdis/jit458 (2014).24136792 10.1093/infdis/jit458
25. Looker KJ Effect of HSV-2 infection on subsequent HIV acquisition: An updated systematic review and meta-analysis Lancet Infect. Dis. 2017 17 1303 1316 10.1016/S1473-3099(17)30405-X 28843576
Looker, K. J. et al. Effect of HSV-2 infection on subsequent HIV acquisition: An updated systematic review and meta-analysis. Lancet Infect. Dis. 17, 1303–1316. 10.1016/S1473-3099(17)30405-X (2017).28843576 10.1016/S1473-3099(17)30405-X
26. Berger JR Houff S Neurological complications of herpes simplex virus type 2 infection Arch. Neurol. 2008 65 596 600 10.1001/archneur.65.5.596 18474734
Berger, J. R. & Houff, S. Neurological complications of herpes simplex virus type 2 infection. Arch. Neurol. 65, 596–600. 10.1001/archneur.65.5.596 (2008).18474734 10.1001/archneur.65.5.596
27. Santpere G Telford M Andres-Benito P Navarro A Ferrer I The presence of human herpesvirus 6 in the brain in health and disease Biomolecules 2020 10 1520 10.3390/biom10111520 33172107
Santpere, G., Telford, M., Andres-Benito, P., Navarro, A. & Ferrer, I. The presence of human herpesvirus 6 in the brain in health and disease. Biomolecules 10, 1520. 10.3390/biom10111520 (2020).33172107 10.3390/biom10111520
28. Readhead B Multiscale analysis of independent Alzheimer’s cohorts finds disruption of molecular, genetic, and clinical networks by human herpesvirus Neuron. 2018 99 64 82 10.1016/j.neuron.2018.05.023 29937276
Readhead, B. et al. Multiscale analysis of independent Alzheimer’s cohorts finds disruption of molecular, genetic, and clinical networks by human herpesvirus. Neuron. 99, 64–82. 10.1016/j.neuron.2018.05.023 (2018).29937276 10.1016/j.neuron.2018.05.023
29. Eimer WA Alzheimer’s disease-associated β-amyloid is rapidly seeded by herpesviridae to protect against brain infection Neuron. 2018 99 56 63 10.1016/j.neuron.2018.06.030 30001512
Eimer, W. A. et al. Alzheimer’s disease-associated β-amyloid is rapidly seeded by herpesviridae to protect against brain infection. Neuron. 99, 56–63. 10.1016/j.neuron.2018.06.030 (2018).30001512 10.1016/j.neuron.2018.06.030
30. Pantry SN Medveczky PG Latency, integration, and reactivation of human herpesvirus-6 Viruses 2017 9 194 10.3390/v9070194 28737715
Pantry, S. N. & Medveczky, P. G. Latency, integration, and reactivation of human herpesvirus-6. Viruses 9, 194. 10.3390/v9070194 (2017).28737715 10.3390/v9070194
31. Bjornevik K Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis Science 2022 375 296 301 10.1126/science.abj8222 35025605
Bjornevik, K. et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science 375, 296–301. 10.1126/science.abj8222 (2022).35025605 10.1126/science.abj8222
32. Chang Y Moore PS Weiss RA Human oncogenic viruses: nature and discovery Philos. Trans. R. Soc. Lond. B. Biol. Sci. 2017 372 20160264 10.1098/rstb.2016.0264 28893931
Chang, Y., Moore, P. S. & Weiss, R. A. Human oncogenic viruses: nature and discovery. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 372, 20160264. 10.1098/rstb.2016.0264 (2017).28893931 10.1098/rstb.2016.0264
33. Söderberg-Nauclér C Geisler J Vetcik K The emerging role of human cytomegalovirus infection in human carcinogenesis: A review of current evidence and potential therapeutic implications Oncotarget 2019 10 4333 4337 10.18632/oncotarget.27016 31303966
Söderberg-Nauclér, C., Geisler, J. & Vetcik, K. The emerging role of human cytomegalovirus infection in human carcinogenesis: A review of current evidence and potential therapeutic implications. Oncotarget 10, 4333–4337. 10.18632/oncotarget.27016 (2019).31303966 10.18632/oncotarget.27016
34. Lee KH Kwon DE Do Han K La Y Han SH Association between cytomegalovirus end-organ diseases and moderate-to-severe dementia: A population-based cohort study BMC Neurol. 2020 20 1 9 10.1186/s12883-020-01776-3 31900128
Lee, K. H., Kwon, D. E., Do Han, K., La, Y. & Han, S. H. Association between cytomegalovirus end-organ diseases and moderate-to-severe dementia: A population-based cohort study. BMC Neurol. 20, 1–9. 10.1186/s12883-020-01776-3 (2020).31900128 10.1186/s12883-020-01776-3
35. Mody PH Marvin KN Hynds DL Hanson LK Cytomegalovirus infection induces Alzheimer’s disease-associated alterations in tau J. Neurovirol. 2023 29 400 415 10.1007/s13365-022-01109-9 37436577
Mody, P. H., Marvin, K. N., Hynds, D. L. & Hanson, L. K. Cytomegalovirus infection induces Alzheimer’s disease-associated alterations in tau. J. Neurovirol. 29, 400–415. 10.1007/s13365-022-01109-9 (2023).37436577 10.1007/s13365-022-01109-9
36. Payne RP Efficacious early antiviral activity of HIV Gag- and Pol-specific HLA-B 2705-restricted CD8+ T cells J. Virol. 2010 84 10543 10557 10.1128/JVI.00793-10 20686036
Payne, R. P. et al. Efficacious early antiviral activity of HIV Gag- and Pol-specific HLA-B 2705-restricted CD8+ T cells. J. Virol. 84, 10543–10557. 10.1128/JVI.00793-10 (2010).20686036 10.1128/JVI.00793-10
37. Hjalgrim H Friborg J Melbye M Arvin A The epidemiology of EBV and its association with malignant disease Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis, Chapter 53 2007 Cambridge University Press
Hjalgrim, H., Friborg, J. & Melbye, M. The epidemiology of EBV and its association with malignant disease. In Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis, Chapter 53 (eds Arvin, A. et al.) (Cambridge University Press, 2007).
38. Vollmers S Lobermeyer A Körner C The new kid on the block: HLA-C, a key regulator of natural killer cells in viral immunity Cells 2021 10 3108 10.3390/cells10113108 34831331
Vollmers, S., Lobermeyer, A. & Körner, C. The new kid on the block: HLA-C, a key regulator of natural killer cells in viral immunity. Cells 10, 3108. 10.3390/cells10113108 (2021).34831331 10.3390/cells10113108
39. Gough SC Simmonds MJ The HLA region and autoimmune disease: Associations and mechanisms of action Curr. Genomics 2007 8 453 465 10.2174/138920207783591690 19412418
Gough, S. C. & Simmonds, M. J. The HLA region and autoimmune disease: Associations and mechanisms of action. Curr. Genomics 8, 453–465. 10.2174/138920207783591690 (2007).19412418 10.2174/138920207783591690
40. Furukawa H The role of common protective alleles HLA-DRB1*13 among systemic autoimmune diseases Genes Immun. 2017 18 1 7 10.1038/gene.2016.40 27829665
Furukawa, H. et al. The role of common protective alleles HLA-DRB1*13 among systemic autoimmune diseases. Genes Immun. 18, 1–7. 10.1038/gene.2016.40 (2017).27829665 10.1038/gene.2016.40
41. Smatti MK Viruses and autoimmunity: A review on the potential interaction and molecular mechanisms Viruses. 2019 11 762 10.3390/v11080762 31430946
Smatti, M. K. et al. Viruses and autoimmunity: A review on the potential interaction and molecular mechanisms. Viruses. 11, 762. 10.3390/v11080762 (2019).31430946 10.3390/v11080762
42. Horst D Ressing ME Wiertz EJ Exploiting human herpesvirus immune evasion for therapeutic gain: Potential and pitfalls Immunol. Cell Biol. 2011 89 359 366 10.1038/icb.2010.129 21301483
Horst, D., Ressing, M. E. & Wiertz, E. J. Exploiting human herpesvirus immune evasion for therapeutic gain: Potential and pitfalls. Immunol. Cell Biol. 89, 359–366. 10.1038/icb.2010.129 (2011).21301483 10.1038/icb.2010.129
43. Heldwein EE Krummenacher C Entry of herpesviruses into mammalian cells Cell Mol. Life Sci. 2008 65 1653 1668 10.1007/s00018-008-7570-z 18351291
Heldwein, E. E. & Krummenacher, C. Entry of herpesviruses into mammalian cells. Cell Mol. Life Sci. 65, 1653–1668. 10.1007/s00018-008-7570-z (2008).18351291 10.1007/s00018-008-7570-z
44. Frye TD Chiou HC Hull BE Bigley NJ The efficacy of a DNA vaccine encoding herpes simplex virus type 1 (HSV-1) glycoprotein D in decreasing ocular disease severity following corneal HSV-1 challenge Arch. Virol. 2002 147 1747 1759 10.1007/s00705-002-0830-6 12209314
Frye, T. D., Chiou, H. C., Hull, B. E. & Bigley, N. J. The efficacy of a DNA vaccine encoding herpes simplex virus type 1 (HSV-1) glycoprotein D in decreasing ocular disease severity following corneal HSV-1 challenge. Arch. Virol. 147, 1747–1759. 10.1007/s00705-002-0830-6 (2002).12209314 10.1007/s00705-002-0830-6
45. Leroux-Roels G Immunogenicity and safety of different formulations of an adjuvanted glycoprotein D genital herpes vaccine in healthy adults: a double-blind randomized trial Hum. Vaccin. Immunother. 2013 9 1254 1262 10.4161/hv.24043 23434737
Leroux-Roels, G. et al. Immunogenicity and safety of different formulations of an adjuvanted glycoprotein D genital herpes vaccine in healthy adults: a double-blind randomized trial. Hum. Vaccin. Immunother. 9, 1254–1262. 10.4161/hv.24043 (2013).23434737 10.4161/hv.24043
46. Heineman TC Cunningham A Levin M Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine Curr. Opin. Immunol. 2019 59 42 48 10.1016/j.coi.2019.02.009 31003070
Heineman, T. C., Cunningham, A. & Levin, M. Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine. Curr. Opin. Immunol. 59, 42–48. 10.1016/j.coi.2019.02.009 (2019).31003070 10.1016/j.coi.2019.02.009
47. Hong J Glycoprotein B antibodies completely neutralize EBV infection of B Cells Front. Immunol. 2022 13 920467 10.3389/fimmu.2022.920467 35711430
Hong, J. et al. Glycoprotein B antibodies completely neutralize EBV infection of B Cells. Front. Immunol. 13, 920467. 10.3389/fimmu.2022.920467 (2022).35711430 10.3389/fimmu.2022.920467
48. Kirchmeier M Enveloped virus-like particle expression of human cytomegalovirus glycoprotein B antigen induces antibodies with potent and broad neutralizing activity Clin. Vaccine Immunol. 2014 21 174 180 10.1128/CVI.00662-13 24334684
Kirchmeier, M. et al. Enveloped virus-like particle expression of human cytomegalovirus glycoprotein B antigen induces antibodies with potent and broad neutralizing activity. Clin. Vaccine Immunol. 21, 174–180. 10.1128/CVI.00662-13 (2014).24334684 10.1128/CVI.00662-13
49. Jasirwan C Furusawa Y Tang H Maeki T Mori Y Human herpesvirus-6A gQ1 and gQ2 are critical for human CD46 usage Microbiol. Immunol. 2014 58 22 30 10.1111/1348-0421.12110 24215487
Jasirwan, C., Furusawa, Y., Tang, H., Maeki, T. & Mori, Y. Human herpesvirus-6A gQ1 and gQ2 are critical for human CD46 usage. Microbiol. Immunol. 58, 22–30. 10.1111/1348-0421.12110 (2014).24215487 10.1111/1348-0421.12110
50. Kawabata A Analysis of a neutralizing antibody for human herpesvirus 6B reveals a role for glycoprotein Q1 in viral entry J. Virol. 2011 85 12962 12971 10.1128/JVI.05622-11 21957287
Kawabata, A. et al. Analysis of a neutralizing antibody for human herpesvirus 6B reveals a role for glycoprotein Q1 in viral entry. J. Virol. 85, 12962–12971. 10.1128/JVI.05622-11 (2011).21957287 10.1128/JVI.05622-11
51. Mukai T Hata A Isegawa Y Yamanishi K Characterization of glycoprotein H and L of human herpesvirus 7 Microbiol. Immunol. 1997 41 43 50 10.1111/j.1348-0421.1997.tb01171.x 9087967
Mukai, T., Hata, A., Isegawa, Y. & Yamanishi, K. Characterization of glycoprotein H and L of human herpesvirus 7. Microbiol. Immunol. 41, 43–50. 10.1111/j.1348-0421.1997.tb01171.x (1997).9087967 10.1111/j.1348-0421.1997.tb01171.x
52. Pertel PE Human herpesvirus 8 glycoprotein B (gB), gH, and gL can mediate cell fusion J. Virol. 2002 76 4390 4400 10.1128/jvi.76.9.4390-4400.2002 11932406
Pertel, P. E. Human herpesvirus 8 glycoprotein B (gB), gH, and gL can mediate cell fusion. J. Virol. 76, 4390–4400. 10.1128/jvi.76.9.4390-4400.2002 (2002).11932406 10.1128/jvi.76.9.4390-4400.2002
53. Wang HY Common polymorphisms in the glycoproteins of human cytomegalovirus and associated strain-specific immunity Viruses 2021 13 1106 10.3390/v13061106 34207868
Wang, H. Y. et al. Common polymorphisms in the glycoproteins of human cytomegalovirus and associated strain-specific immunity. Viruses 13, 1106. 10.3390/v13061106 (2021).34207868 10.3390/v13061106
54. James LM Georgopoulos AP Immunogenetic epidemiology of dementia and Parkinson’s Disease in 14 continental European countries: Shared human leukocyte antigen (HLA) profiles J. Immunological Sci. 2021 5 16 26 10.29245/2578-3009/2021/12.1209
James, L. M. & Georgopoulos, A. P. Immunogenetic epidemiology of dementia and Parkinson’s Disease in 14 continental European countries: Shared human leukocyte antigen (HLA) profiles. J. Immunological Sci. 5, 16–26. 10.29245/2578-3009/2021/12.1209 (2021).10.29245/2578-3009/2021/12.1209
55. Hurley CK Common, intermediate and well-documented HLA alleles in world populations: CIWD version 3.0.0 HLA. 2020 95 516 531 10.1111/tan.13811 31970929
Hurley, C. K. et al. Common, intermediate and well-documented HLA alleles in world populations: CIWD version 3.0.0. HLA. 95, 516–531. 10.1111/tan.13811 (2020).31970929 10.1111/tan.13811
56. Reynisson B Alvarez B Paul S Peters B Nielsen M NetMHCpan-4.1 and NetMHCIIpan-4.0: Improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data Nucleic Acids Res. 2020 48 0449 0454 10.1093/nar/gkaa379
Reynisson, B., Alvarez, B., Paul, S., Peters, B. & Nielsen, M. NetMHCpan-4.1 and NetMHCIIpan-4.0: Improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 48, 0449–0454. 10.1093/nar/gkaa379 (2020).10.1093/nar/gkaa379
57. IEDB Analysis Resource. Accessed on April 11, 2024. http://tools.iedb.org/mhci/
58. Charonis S James LM Georgopoulos AP In silico assessment of binding affinities of three dementia-protective Human Leukocyte Antigen (HLA) alleles to nine human herpes virus antigens Curr. Res. Transl. Med. 2020 68 211 216 10.1016/j.retram.2020.06.002 32624427
Charonis, S., James, L. M. & Georgopoulos, A. P. In silico assessment of binding affinities of three dementia-protective Human Leukocyte Antigen (HLA) alleles to nine human herpes virus antigens. Curr. Res. Transl. Med. 68, 211–216. 10.1016/j.retram.2020.06.002 (2020).32624427 10.1016/j.retram.2020.06.002
59. Charonis S Tsilibary EP Georgopoulos A SARS-CoV-2 virus and Human Leukocyte Antigen (HLA) Class II: Investigation in silico of binding affinities for COVID-19 protection and vaccine development J. Immunol. Sci. 2020 4 12 23 10.29245/2578-3009/2020/4.1198
Charonis, S., Tsilibary, E. P. & Georgopoulos, A. SARS-CoV-2 virus and Human Leukocyte Antigen (HLA) Class II: Investigation in silico of binding affinities for COVID-19 protection and vaccine development. J. Immunol. Sci. 4, 12–23. 10.29245/2578-3009/2020/4.1198 (2020).10.29245/2578-3009/2020/4.1198
60. Charonis SA Tsilibary EP Georgopoulos AP In silico investigation of binding affinities between human leukocyte antigen class I molecules and SARS-CoV-2 virus spike and ORF1ab proteins Explor. Immunol. 2021 1 16 26 10.37349/ei.2021.00003
Charonis, S. A., Tsilibary, E. P. & Georgopoulos, A. P. In silico investigation of binding affinities between human leukocyte antigen class I molecules and SARS-CoV-2 virus spike and ORF1ab proteins. Explor. Immunol. 1, 16–26. 10.37349/ei.2021.00003 (2021).10.37349/ei.2021.00003
61. Babicki S Heatmapper: Web-enabled heat mapping for all Nucleic Acids Res. 2016 44 W147 W153 10.1093/nar/gkw419 27190236
Babicki, S. et al. Heatmapper: Web-enabled heat mapping for all. Nucleic Acids Res. 44, W147–W153. 10.1093/nar/gkw419 (2016).27190236 10.1093/nar/gkw419
